多发性骨髓瘤操作性治愈的要求
多发性骨髓瘤通常被认为不可治愈,但近年治疗进步使操作性治愈成为现实目标。新药联合或不联合高剂量化疗/自体移植显示,治疗深度与结局相关,MRD阴性可改善无进展生存,MRD状态正成为公认的强预后因素。本文讨论了MRD阴性对PFS和长期疾病控制的影响,作为潜在治愈的替代指标。
要点
- MRD阴性可改善多发性骨髓瘤患者的无进展生存,并作为潜在治愈的替代标志。
- MRD评估需关注检测灵敏度、评估时机与持续性、治疗类型与时长、细胞遗传学及患者年龄。
- 年轻患者接受最活跃药物联合自体移植及维持治疗,操作性治愈概率最高。
核心结论
- 随着治疗进步,多发性骨髓瘤的操作性治愈正成为现实目标。
- MRD阴性作为潜在治愈的替代标志,与改善的无进展生存相关。
研究设计与样本
- 本文为综述,讨论了MRD阴性对多发性骨髓瘤PFS和长期疾病控制的影响。
主要发现
- 新药联合或不联合高剂量化疗或自体移植显示,治疗深度与结局相关。
- MRD阴性已被证明与改善的无进展生存相关,MRD状态正成为公认的强预后因素。
关键数值与推荐
- MRD评估需关注检测灵敏度或最低检测限(所用方法)。
- MRD评估需关注评估时机与持续性。
- MRD评估需关注治疗类型与时长。
- MRD评估需关注初始预后因素(最重要的是细胞遗传学)。
- MRD评估需关注患者年龄。
临床怎么用
- 目前操作性治愈概率最高的是接受最活跃药物联合自体移植及维持治疗的年轻患者。
- 老年患者接受抗CD38抗体为基础的一线治疗,也可能实现操作性治愈。
- 将MRD作为临床试验的替代终点,可缩短试验周期,促进个性化管理和长期治愈。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma is usually considered an incurable disease. However, with the therapeutic improvement observed in the past few years, achievement of an operational cure is increasingly becoming a realistic goal. The advent of novel agents, with or without high-dose chemotherapy or autologous transplantation, revealed a correlation between depth of response to treatment and outcome. Of note, minimal residual disease (MRD) negativity has been shown to be associated with improved progression-free survival (PFS), and MRD status is becoming a well-established and strong prognostic factor. Here, we discuss the impact of MRD negativity on PFS and long-term disease control, as a surrogate for potential cure in a significant proportion of patients. MRD value and impact should be examined by focusing on different parameters: (1) sensitivity or lower limit of detection level (method used), (2) timing of assessment and sustainability, (3) type and duration of treatment, (4) initial prognostic factors (most importantly cytogenetics), and (5) patient age. Currently, the highest probability of operational cure is in younger patients receiving the most active drugs, in combination with autologous transplantation followed by maintenance therapy. Older patients are also likely to achieve operational cure, especially if they are treated upfront with anti-CD38 antibody-based therapy but also with novel immunotherapies in future protocols. Incorporation of MRD as a surrogate end point in clinical trials would enable shorter trials, leading to more personalized management and achievement of long-term cure.
引用
- Mohty M, Avet-Loiseau H, Harousseau JL, et al. Requirements for operational cure in multiple myeloma. Blood. 2021. PMID: 34324647. doi:10.1182/blood.2021012854
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。